Browsing Tag

Codiaks

Data from Codiak’s exoASO™-STAT6 Preclinical Development Program for the Treatment of Primary and…

Jason Junior Feb 19, 2022

– Unprecedented monotherapy activity via macrophage reprogramming in preclinical models – – Phase 1 study expected to begin in 1H 2022 – CAMBRIDGE, Mass., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK), a…

Health

Codiak’s Engineered Exosomes Promote T Cell and Antibody Responses to SARS-CoV-2 in vivo, Supporting…

Jason Junior Dec 2, 2021

CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines,…